Karin Kristina Amundson

Title: Innovations of Karin Kristina Amundson

Introduction

Karin Kristina Amundson is a notable inventor based in San Diego, CA. She has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 3 patents, her work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

One of her latest patents focuses on human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1). This invention relates to antibodies that bind to the extracellular domain of ALK-1 and function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The patent also covers heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies, as well as nucleic acid molecules encoding these immunoglobulins. Additionally, it includes methods for making human anti-ALK-1 antibodies, compositions comprising these antibodies, and methods of using them. The invention also extends to transgenic animals or plants that incorporate the nucleic acid molecules of this invention.

Career Highlights

Karin has worked with prominent companies in the biotechnology sector, including Amgen Fremont Inc. and Pfizer Corporation. Her experience in these organizations has contributed to her expertise in developing innovative solutions in the field.

Collaborations

Throughout her career, Karin has collaborated with notable professionals, including Michael Aidan North and Vahe Bedian. These collaborations have likely enriched her research and development efforts.

Conclusion

Karin Kristina Amundson's contributions to biotechnology through her patents and collaborations highlight her role as an influential inventor. Her work continues to pave the way for advancements in medical therapies.